Viridian Therapeutics, Inc. (VRDN)
24.18
+0.16
(+0.67%)
USD |
NASDAQ |
Aug 25, 16:00
24.18
0.00 (0.00%)
After-Hours: 19:59
Viridian Therapeutics EPS Diluted (Quarterly) : -1.178 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.178 |
| March 31, 2026 | -1.026 |
| December 31, 2025 | -1.080 |
| September 30, 2025 | -0.423 |
| June 30, 2025 | -1.235 |
| March 31, 2025 | -1.068 |
| December 31, 2024 | -0.8076 |
| September 30, 2024 | -1.155 |
| June 30, 2024 | -1.018 |
| March 31, 2024 | -0.7945 |
| December 31, 2023 | -1.346 |
| September 30, 2023 | -1.092 |
| June 30, 2023 | -1.273 |
| March 31, 2023 | -1.613 |
| December 31, 2022 | -1.129 |
| September 30, 2022 | -0.8566 |
| June 30, 2022 | -1.062 |
| March 31, 2022 | -0.9834 |
| December 31, 2021 | -1.309 |
| September 30, 2021 | -1.256 |
| June 30, 2021 | -2.216 |
| March 31, 2021 | -2.913 |
| December 31, 2020 | -23.07 |
| September 30, 2020 | -1.477 |
| June 30, 2020 | -1.819 |
| Date | Value |
|---|---|
| March 31, 2020 | -2.653 |
| December 31, 2019 | -4.687 |
| September 30, 2019 | -5.420 |
| June 30, 2019 | -4.307 |
| March 31, 2019 | -5.648 |
| December 31, 2018 | -5.018 |
| September 30, 2018 | -4.399 |
| June 30, 2018 | -4.35 |
| March 31, 2018 | -2.70 |
| December 31, 2017 | -4.35 |
| September 30, 2017 | -4.05 |
| June 30, 2017 | -5.10 |
| March 31, 2017 | -9.00 |
| December 31, 2016 | -107.69 |
| September 30, 2016 | -1557.00 |
| June 30, 2016 | -51.75 |
| March 31, 2016 | -58.50 |
| December 31, 2015 | -63.04 |
| September 30, 2015 | -87.75 |
| June 30, 2015 | -74.25 |
| March 31, 2015 | -101.25 |
| December 31, 2014 | -134.32 |
| September 30, 2014 | -96.75 |
| June 30, 2014 | -254.25 |
| December 31, 2013 | -11.61 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -127.12M |
| Revenue (Quarterly) | 0.284M |
| Total Expenses (Quarterly) | 127.40M |
| Enterprise Value | 2.079B |
| Gross Profit Margin (Quarterly) | 58.80% |
| Profit Margin (Quarterly) | -44.76K% |
| Earnings Yield | -15.34% |
| Normalized Earnings Yield | -15.50 |